| Gene symbol | PROM1 | Synonyms | AC133, CD133, CORD12, MCDR2, MSTP061, PROML1, RP41, STGD4 | Type of gene | protein-coding |
| Chromosome | 4 | Map location | 4p15.32 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | prominin 1 | ||||
| Gene symbol | CD44 | Synonyms | CDW44, CSPG8, ECM-III, ECMR-III, H-CAM, HCELL, HUTCH-1, HUTCH-I, Hermes-1, IN, LHR, MC56, MDU2, MDU3, MIC4, Pgp1 | Type of gene | protein-coding |
| Chromosome | 11 | Map location | 11p13 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | CD44 molecule (IN blood group) | ||||
| GTO ID | GTC3206 |
| Trial ID | NCT05577091 |
| Disease | Glioblastoma |
| Altered gene | CD44|CD133 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | Tris CAR-T cells |
| Generation | 4th |
| Phase | Phase1 |
| Recruitment status | Not Recruiting |
| Title | Tris-CAR-T Cell Therapy for Recurrent Glioblastoma |
| Year | 2022 |
| Country | China |
| Company sponsor | Beijing Tiantan Hospital |
| Other ID(s) | TTSW2021-01 |
| Cohort1: dose level 1 | |||||||||
|
|||||||||
| Cohort2: dose level 2 | |||||||||
|
|||||||||
| Cohort3: dose level 3 | |||||||||
|
|||||||||